65,437 trials
Advanced Parkinson's Disease
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period — 7; 5; 0; 0 participants
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 1; 6; 1; 0 participants
Bacteremia · Fungemia · Bloodstream Infection
Primary: Duration of Antimicrobial Therapy (Hours) — 44; 42; 42; 8.2 hours — p=0.92
Lesion of Stomach
Primary: Total Cumulative Mucosal Visibility Score — 5.78; 8.89 units
Mitral Valve Insufficiency
Primary: Postoperative Fentanyl — 4.51; 6.14 microgram/kilogram
Glioma
Primary: Maximum Tolerated Dose (MTD) of Capecitabine. — 650 milligrams
Overweight · Obese
Primary: Serum IL-6 — 42.4; 34.3 (pg*hr)/mL
Rupture · Venous Thromboembolism · Venous Thrombosis
Primary: Venous Thromboembolic Events (VTE) — 26; 14 participants — p=0.042
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
Major Depressive Disorder · Irritability
Primary: Change From Baseline to Week 6 in SIS Total Score — -21.13 units on a scale
Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Non-ocular Adverse Events. — 17; 12; 37; 35 participants
Lymphoma, B-Cell · Follicular Lymphoma
Primary: Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I) — 1.62 mg/m^2
Malocclusion
Primary: Rate of Orthodontic Anterior Alignment in Millimetres Per Week (mm/wk) by Means of Little's Irregularity Index (LII) for Extraoral OrthoPulse® PBM and Non-OrthoPulse®…
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.7; 4.8 months — p=0.0006
Anemia
Primary: Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)…